1.
Cartron G, Hourcade-Potelleret F, Morschhauser F, Salles G, Wenger M, Truppel-Hartmann A, Carlile DJ. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica [Internet]. 2016Feb.1 [cited 2026Nov.16];101(2):226-34. Available from: https://haematologica.org/article/view/7629